Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. announced a change in its board of supervisors, with Mr. Yuan Yexing resigning as the employee representative supervisor to focus on personal development. The board expressed gratitude for his contributions and confirmed there were no disagreements with Mr. Yuan. Concurrently, Mr. Liu Zhiyong has been appointed as the new employee representative supervisor. Mr. Liu, who has been with the company since 2020 and has extensive experience in the biopharmaceutical industry, assumes his new role on January 31, 2025. This transition marks a continued focus on maintaining strong leadership within the company’s supervisory structure.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, primarily involved in the development of biopharmaceuticals. The company is engaged in the research and production of monoclonal antibody drugs and other biologics, with a focus on innovation and expanding its presence in the global market.
YTD Price Performance: -29.28%
Average Trading Volume: 675,461
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$9.11B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.